Home | Publications | Company Information | Top 50 Pharma | Schering-Plough place holder
place holder place holder

Schering-Plough

Schering-Plough Corporation

PharmaVitae Profile

Publication Date   July 2008
Publisher   Datamonitor
Product Type   Report
Pages   164
ISBN Number   not applicable
Product Code   DAT1466
Ask a question about this product?

Price £3,010.00

approximately: $4,618 | €3,541

Summary


Introduction

This analysis examines the historical and forecast performance for Schering-Plough in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark Schering-Plough's performance against key rivals in the ethical pharmaceutical sector
  • Analyze the impact of Schering-Plough's acquisition of Organon Biosciences, completed in 2007
  • Assess the diversity of Schering-Plough's product portfolio in light of forecast declining sales for its recent sales growth driver Zetia/Vytorin

Content


  • CHAPTER 1 ABOUT THIS PROFILE
    • Executive summary
    • Quarterly news update
    • Company introduction
    • Company sales
    • Company financials
    • Key products and competitors
    • Data sourcing
    • Sales data
    • Analyst consensus
  • CHAPTER 2 EXECUTIVE SUMMARY
    • Key findings
    • Prescription pharmaceutical sales performance, 2001-13
    • Financial performance, 2001-13
    • Schering-Plough: PharmaVitae forecasts at a glance
    • Strategic insight
    • Five principal events orchestrate SGP's performance as action agenda progresses
    • Business-model crumbles under pressure from loratadine generics
    • Widening portfolio to helps restore sales growth
    • SGP 'Build the Base' phase in a single move through the OBS acquisition
    • ENHANCE trial fallout threatens Zetia/Vytorin income stream
    • Cost-cutting implementations and pipeline to drive long-term profit growth
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • CHAPTER 3 QUARTERLY NEWS UPDATE
    • Key findings
    • Product developments
    • Deals and alliances
    • Product deals
    • Technology deals
    • M&A activity
    • Company announcements
    • Future product milestones
  • CHAPTER 4 COMPANY STRUCTURE
    • Key findings
    • Company overview
    • Company history
    • M&A history
    • Schering Corp merger with Plough Corp
    • Neogenesis
    • Organon Biosciences
    • M&A strategy
  • CHAPTER 5 COMPANY SALES
    • Key findings
    • Prescription pharmaceutical sales and growth rate analysis, 2001-13
    • Historical analysis
    • Forecast analysis
    • Product analysis
    • Product analysis, 2001-07
    • Product analysis, 2007-13
    • Therapy area analysis
    • Therapy area analysis, 2001-07
    • Therapy area analysis, 2007-13
    • Therapy area focus, 2001-13
    • Geographic analysis
    • Geographic analysis, 2001-07
    • Geographic analysis, 2007-13
    • Geographic focus, 2001-13
    • Launch/core/expiry analysis
    • Explanation of launch/core/expiry analysis
    • Launch analysis, 2007-13
    • Core analysis, 2007-13
    • Expiry analysis, 2007-13
    • Launch/core/expiry configuration, 2007-13
    • Molecule type analysis
    • Molecule type analysis, 2001-07
    • Molecule type analysis, 2007-13
    • Externalization analysis
    • Externalization analysis, 2001-07
    • Externalization analysis, 2007-13
  • CHAPTER 6 COMPANY FINANCIALS
    • Key findings
    • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07
    • Financial statements, 2001-07
    • Profit and loss account, 2001-07
    • Balance sheet, 2001-07
    • Operating costs and profit analysis
    • Operating costs and profit analysis, 2001-07
    • Operating cost ratio and profit margin analysis, 2001-07
    • Operating cost ratio and profit margin analysis, 2007-13
    • Operating costs and profit analysis, 2007-13
    • Return on capital employed analysis
    • Capital employed analysis, 2001-07
    • Return on capital employed (RoCE) analysis, 2001-07
    • Market capitalization analysis
    • Market capitalization analysis 2001-07
    • Total shareholder returns analysis 2001-07
  • CHAPTER 7 KEY PRODUCTS AND COMPETITORS
    • Key findings
    • Overview
    • Urology & gender-specific health
    • NuvaRing
    • Sales forecasts
    • Respiratory
    • Nasonex
    • Sales forecast
    • Infectious diseases
    • Intron franchise
    • Sales forecasts
    • Immunology & inflammation
    • Remicade/golimumab
    • Sales forecasts
    • Central nervous system
    • Asenapine
    • Sales forecasts
    • Bridion
    • Sales forecasts
    • Cardiovascular
    • Zetia/Vytorin
    • Sales forecast
    • Oncology
    • Temodar
    • Sales forecasts
  • CHAPTER 8 APPENDIX
    • R&D pipeline
    • References
    • Abbreviations
  • List of Tables
    • Table 1: Schering-Plough - PharmaVitae forecasts at a glance
    • Table 2: OBS acquisition builds the base
    • Table 3: Key product developments, Q1 2008
    • Table 4: Schering-Plough product deals and alliances, Q1 2008
    • Table 5: Schering-Plough technology deals and alliances, Q1 2008
    • Table 6: Schering-Plough M&A activity, Q1 2008
    • Table 7: Schering-Plough company announcements, 2008
    • Table 8: Schering-Plough future product milestones 2008-09
    • Table 9: Schering-Plough product portfolio overview, global sales ($m), 2001-07
    • Table 10: Schering-Plough product portfolio overview, global sales ($m), 2007-13
    • Table 11: Schering-Plough therapy portfolio overview, sales ($m), 2001-07
    • Table 12: Schering-Plough therapy portfolio overview, sales ($m), 2007-13
    • Table 13: Schering-Plough portfolio overview by geographic region, sales ($m), 2001-07
    • Table 14: Schering-Plough portfolio overview by geographic region, sales ($m), 2007-13
    • Table 15: Schering-Plough launch portfolio overview ($m), 2007-13
    • Table 16: Schering-Plough core portfolio overview ($m), 2007-13
    • Table 17: Schering-Plough expiry portfolio overview ($m), 2007-13
    • Table 18: Schering-Plough portfolio overview by molecule type ($m), 2001-07
    • Table 19: Schering-Plough product portfolio overview by molecule type ($m), 2007-13
    • Table 20: Schering-Plough product portfolio overview by source ($m), 2001-07
    • Table 21: Schering-Plough product portfolio overview by source ($m), 2007-13
    • Table 22: Total Schering-Plough sales by business unit ($m), 2001-07
    • Table 23: Schering-Plough profit and loss account ($m), 2001-07
    • Table 24: Schering-Plough balance sheet ($m), 2001-07
    • Table 25: Schering-Plough operating revenue/cost analysis ($m), 2001-07
    • Table 26: Schering-Plough operating cost ratio analysis (% of total revenues), 2001-07
    • Table 27: Schering-Plough operating cost ratio analysis (% of total revenues), 2007-13
    • Table 28: Schering-Plough operating revenue/cost analysis ($m), 2007-13
    • Table 29: Schering-Plough capital employed ($m), 2001-07
    • Table 30: Schering-Plough EBIT return on capital employed ($m), 2001-07
    • Table 31: Schering-Plough EBIT pre-tax return/Capital employed driver analysis ($m), 2001-07
    • Table 32: SGP market capitalization vs. S&P 500 ($ billion), 2001-07
    • Table 33: Schering-Plough total shareholder returns (annual %), 2001-07
    • Table 34: Key products overview, sales ($m)
    • Table 35: NuvaRing: overview
    • Table 36: NuvaRing: sales forecast ($m), 2007-13
    • Table 37: Oral contraceptive market, sales ($m), 2001-13
    • Table 38: Nasonex: overview
    • Table 39: Nasonex: sales forecast ($m), 2007-13
    • Table 40: Top four nasal corticosteroids, sales ($m), 2001-07
    • Table 41: Peg-Intron: overview
    • Table 42: Intron A: overview
    • Table 43: Rebetol: overview
    • Table 44: Peg-Intron & Intron A: sales forecast ($m), 2007-13
    • Table 45: Rebetol: sales forecast ($m), 2007-13
    • Table 46: Remicade: overview
    • Table 47: Golimumab: overview
    • Table 48: Remicade: sales forecast ($m), 2007-13
    • Table 49: Golimumab: sales forecast ($m), 2006-12
    • Table 50: Anti-TNF market overview
    • Table 51: Asenapine: overview
    • Table 52: Asenapine: sales forecast ($m), 2007-13
    • Table 53: Bridion: overview
    • Table 54: Bridion: sales forecast ($m), 2007-13
    • Table 55: Phase III efficacy results of Bridion vs Neostigmine
    • Table 56: Zetia/Vytorin: overview
    • Table 57: Zetia/Vytorin: sales forecast ($m), 2007-13
    • Table 58: Major dyslipidemia therapeutics, sales ($m), 2001-07
    • Table 59: Temodar: overview
    • Table 60: Temodar: sales forecast ($m), 2007-13
    • Table 61: Schering-Plough's R&D pipeline (Phase I-registration)
    • Table 62: Schering-Plough's indication broadening pipeline (Phase I-registration)
  • List of Figures
    • Figure 1: Schering-Plough prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
    • Figure 2: Schering-Plough financial performance ($m), 2001-13
    • Figure 3: Five events dominate SGP's five-phase action agenda timeline
    • Figure 4: Claritin triggered profit decay ($m), 2001-04
    • Figure 5: SGP's portfolio expansion, sales ($m), 2001-07
    • Figure 6: Schering-Plough SWOT analysis
    • Figure 7: Schering-Plough prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
    • Figure 8: Schering-Plough key sales growth driver & resistors ($m), 2001-07
    • Figure 9: Schering-Plough key sales growth drivers & resistors ($m), 2007-13
    • Figure 10: Schering-Plough prescription pharmaceutical sales by therapy area ($m), 2001-13
    • Figure 11: Schering-Plough prescription pharma sales by therapy area, (% of total), 2001-13
    • Figure 12: Schering-Plough prescription pharmaceutical sales by geographic region ($m), 2001-13
    • Figure 13: Schering-Plough drivers and resistors by geographic region, sales ($m), 2001-07
    • Figure 14: Schering-Plough drivers and resistors by geographic region, sales ($m), 2007-13
    • Figure 15: Schering-Plough prescription pharmaceutical sales by geographic region (% of total), 2001-13
    • Figure 16: Schering-Plough launch/core/expiry configuration ($m), 2007-13
    • Figure 17: Schering-Plough prescription pharmaceutical sales by molecule type ($m), 2001-13
    • Figure 18: Schering-Plough growth drivers & resistors by molecule type ($m), 2007-13
    • Figure 19: Schering-Plough prescription pharmaceutical sales by source ($m), 2001-13
    • Figure 20: Schering-Plough growth drivers & resistors by source ($m), 2001-07
    • Figure 21: Schering-Plough growth drivers & resistors by source ($m), 2007-13
    • Figure 22: Schering-Plough operating revenue/cost analysis ($m), 2001-13
    • Figure 23: Schering-Plough operating cost ratio analysis (% of total revenues), 2001-13
    • Figure 24: Schering-Plough return on capital employed, EBIT margin and capital turnover, 2001-07
    • Figure 25: Return on capital employed formula
    • Figure 26: SGP market cap vs. S&P 500 ($ billion), 2001-07
    • Figure 27: SGP total shareholder returns vs. S&P 500, 2001-07 ($m)
    • Figure 28: Schering-Plough's Hep C franchise, sales ($m), 2001-13
    • Figure 29: Dyslipidemia treatment sales ($m), 2001-07